Metabolize secures $3.2 million in seed funding to fuel the January 2027 launch of its NATLEAN product line and scale its proprietary Precision Metabolite™ Technology platform.
Metabolize raised $3.2 million in seed financing to launch NATLEAN and expand its product portfolio, indicating positive growth prospects.
Consumer health firm Metabolize has successfully raised $3.2 million in seed financing to accelerate its growth strategy. The capital will fund the January 2027 launch of NATLEAN and support the expansion of its proprietary Precision Metabolite™ Technology product portfolio.
The funds are earmarked for the January 2027 launch of the NATLEAN product line and the expansion of Metabolize's proprietary Precision Metabolite™ Technology portfolio.